{"filings":[{"id":2467796,"accession_number":"0001104659-26-100860","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-08-25T20:52:55+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance's ampreloxetine misses primary endpoint in Phase 3 CYPRESS nOH/MSA study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint (OHSA composite change at week 8 of randomized withdrawal) not statistically significant; secondary endpoints showed similar trends.","FDA in May 2026 said existing data won't support approval; Type C meeting requested to align on future pivotal trial design.","Post hoc analysis (confirmed symptomatic nOH, n=47): average OHSA diff -1.06 (p=0.001), OHDAS -1.27 (p<0.001), OHQ -1.24 (p<0.001).","Pressor effect confirmed via BP, heart rate, norepinephrine changes; safety consistent with prior studies, no worsening supine hypertension.","Company previously announced acquisition by Zymeworks (June 29, 2026), subject to shareholder approval; deal context for this update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2144957,"accession_number":"0001104659-26-093066","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-08-10T12:35:01+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Q2: YUPELRI collab revenue up 11% to $20.7M; non-GAAP ops income $9.5M; Zymeworks deal on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.9M vs net income $54.8M in Q2 2025 (2025 included $75.1M gain on TRELEGY royalty sale); non-GAAP ops income $9.5M vs loss $4.2M.","YUPELRI US net sales $70.7M (Viatris), up 7% YoY; collaboration revenue $20.7M, up 11% YoY; TRELEGY global net sales ~$1.0B in Q2.","Opex down 35% YoY excl. restructuring/transaction costs; restructuring to cut opex ~60% vs 2025's $111.1M, ~$70M savings in 2H 2026.","Zymeworks acquisition at $17.00/share cash plus CVR (80% of ampreloxetine monetization) expected to close 2H 2026; cash $388M, no debt.","High confidence in $100M Royalty Pharma milestone if FY 2026 TRELEGY net sales reach ~$3.5B; FY 2025 $3.9B triggered $50M paid Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1314877,"accession_number":"0001104659-26-078453","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-06-29T10:30:58+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Theravance Biopharma to be acquired by Zymeworks for $17.00/share cash plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders receive $17.00/share cash (~$929M equity value) plus a CVR for 80% of net proceeds from ampreloxetine monetization over ten years.","Transaction represents a 22% premium to TBPH's March 3, 2026 close and 10% premium to VWAP since then.","Merger expected to close in H2 2026, subject to shareholder vote (2/3 majority), HSR clearance, and customary conditions.","Termination fees: $32.515M payable by either party under certain circumstances.","Parent's debt financing commitment from OMERS Life Sciences; no financing condition for closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1224276,"accession_number":"0001104659-26-076857","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-06-23T21:02:45+00:00","items":["5.02"],"status":"ready","headline":"Theravance Biopharma SVP Áine Miller to depart Nov 15, 2026 as part of restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Miller, SVP Development and Head of Ireland Office, will terminate on Nov 15, 2026.","Termination is part of the restructuring announced by the Company in March 2026.","Company will make a special pension contribution of $250,000 within 30 days of termination.","Dr. Miller received a grant of 18,750 RSUs for continued service through the Termination Date.","Compromise agreement and side letter entered into on June 19, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1029449,"accession_number":"0001104659-26-073559","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-06-12T20:59:44+00:00","items":["5.07"],"status":"ready","headline":"Theravance Biopharma shareholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with >98% of votes cast in favor, including Laurie Smaldone Alsup and Susannah Gray.","Ernst & Young LLP ratified as independent auditor for FY 2026 with 46.5M for, 572.9K against.","Non-binding advisory resolution on named executive officer compensation approved with 42.6M for, 221.2K against.","Proxies represented 91.4% of outstanding shares (47.06M), quorum established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93853,"accession_number":"0001104659-26-056733","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).","Net loss $4.9M vs. $13.6M YoY; Non-GAAP net income from operations $0.6M vs. loss of $8.6M.","Operating expenses down ~20% YoY (ex-restructuring); restructuring on track for ~60% reduction by Q3 2026.","All Hatch-Waxman YUPELRI litigation resolved; settlement with Mankind Pharma sets licensed launch date April 23, 2039.","Cash $395M, no debt; Strategic Review Committee evaluating sale or other value-maximizing alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":17699000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105803,"accession_number":"0001104659-26-036870","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent suit; generic license start April 23, 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.","Royalty-free license granted for generic version on or after April 23, 2039, subject to customary exceptions.","All pending Hatch-Waxman litigation relating to YUPELRI now resolved; settlement subject to DOJ/FTC review.","Involves patents 11,484,531, 12,048,692 and 12,285,417; parties include Theravance subsidiaries and Mylan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105802,"accession_number":"0001104659-26-031795","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.","TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.","Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.","Cash ~$400M at end Q1 2026; no debt.","Strategic Review Committee accelerating evaluation of alternatives including potential sale of company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105801,"accession_number":"0001104659-26-022572","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","2.05","7.01","9.01"],"status":"ready","headline":"Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.","Organizational restructuring to reduce cost base ~60% (~$70M) and impact ~50% of workforce; R&D wound down, G&A cut ~50%.","Board's Strategic Review Committee accelerating evaluation of alternatives including a sale of the company.","Preliminary cash $326.5M at Q4 2025; expected ~$400M at Q1 2026 after $25M YUPELRI and $50M TRELEGY milestones received.","YUPELRI FY2025 net sales $266.6M (+12% YoY); company expects ~$60-70M annualized cash flow from restructuring and YUPELRI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105800,"accession_number":"0001104659-26-002726","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Theravance Biopharma holds investor meetings with January 2026 corporate slide deck; no new financials or guidance","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management team conducting one-on-one meetings with analysts and investors in San Francisco from Jan 12-15, 2026.","Slide deck furnished as Exhibit 99.1 contains corporate overview but no material new information beyond prior disclosures.","Filing under Regulation FD; no financial updates, pipeline changes, or guidance adjustments disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122085,"accession_number":"0001104659-25-119032","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance holds ampreloxetine KOL event; AGM set for June 12, 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual KOL investor event for ampreloxetine held Dec. 8, 2025; slide deck furnished as exhibit.","2026 Annual General Meeting scheduled for June 12, 2026 in Dublin, Ireland.","Proxy materials will be filed with SEC and made available to shareholders prior to the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122084,"accession_number":"0001104659-25-109146","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).","Non-GAAP net income from ops $2.3M (vs -$2.9M); GAAP net income $3.6M (includes $6.5M tax benefit).","Phase 3 CYPRESS of ampreloxetine (MSA-nOH): open-label done; topline data Q1 2026.","Cash $333M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.","Company achieves non-GAAP breakeven, underscoring financial discipline."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":61573000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138791,"accession_number":"0001104659-25-082048","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance Biopharma completes Phase 3 enrollment for ampreloxetine in nOH due to MSA; topline Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in open-label portion of pivotal Phase 3 CYPRESS study (NCT05696717) for nOH due to MSA.","Expected topline results in Q1 2026; if positive, plans for expedited NDA submission and priority FDA review.","Ampreloxetine has Orphan Drug Designation in the U.S.; addresses ~40,000 patients with symptomatic nOH due to MSA.","Primary endpoint is change in OHSA composite score from randomized-withdrawal baseline to Week 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138790,"accession_number":"0001104659-25-080470","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.","Cipla granted royalty-free license to market generic version in U.S. on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation remains pending against Mankind Pharma Ltd. and affiliates (another ANDA filer)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138789,"accession_number":"0001104659-25-076837","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.","Completed sale of TRELEGY royalty interest to GSK for $225M; net gain of $75.1M.","Pivotal Phase 3 CYPRESS study enrollment nearing completion; top-line data ~6 months later.","Cash $339M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.","Non-GAAP net loss from operations improved to $4.2M from $6.3M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":41583000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156245,"accession_number":"0001104659-25-062722","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.","Approval triggers $7.5M milestone from Viatris, expected Q3 2025; eligible for up to $37.5M in sales milestones and 14-20% tiered royalties.","Viatris responsible for all development/commercialization; Theravance incurs no commercial costs in China.","Theravance cash $131M (Mar 31), plus $225M from TRELEGY royalty sale and up to $150M near-term TRELEGY milestones.","Theravance nearing completion of enrollment in open-label portion of CYPRESS study of ampreloxetine for nOH in MSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156244,"accession_number":"0001104659-25-056996","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).","Eugia granted royalty-free license to market generic version on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation continues against two other ANDA filers: Cipla and Mankind Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156243,"accession_number":"0001104659-25-055100","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.","Retains right to up to $150M in milestones from Royalty Pharma on 2025/2026 net sales.","First outcome from Strategic Review Committee formed Nov 2024; board committed to returning excess capital.","Total potential lifetime value from Trelegy monetization now $1.525B including prior $1.1B upfront.","2025 financial guidance unchanged; company continues to focus on YUPELRI and ampreloxetine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156242,"accession_number":"0001104659-25-051050","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Theravance Biopharma holds 2025 annual meeting, elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Rick E. Winningham, Jeremy T. Grant, Susannah Gray, Donal O'Connor as Class II directors.","Ratification of Ernst & Young as auditor for FY2025 approved: 45,165,816 for, 578,070 against.","Advisory say-on-pay resolution approved: 30,154,992 for, 374,257 against, 9,536,311 abstain.","Quorum of 45,746,079 shares (91.5% outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156241,"accession_number":"0001104659-25-046137","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.","Net loss $13.6M vs $11.7M in Q1 2024; Non-GAAP net loss from ops $8.6M vs $4.5M.","Revenue $15.4M entirely from Viatris collaboration, up 6% YoY.","Cash $131M, no debt; reaffirming all financial guidance.","CYPRESS study open label enrollment nearing completion, final patient expected by late summer; top-line data ~6 months later."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":15388000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174705,"accession_number":"0001104659-25-017438","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.","TRELEGY global net sales of $3.46B in FY 2024 triggered a $50M milestone from Royalty Pharma, received in February 2025.","Company ended Q4 2024 with $88M cash, and CYPRESS study on track to enroll final patient by mid-2025.","Q4 2024 total revenue was $18.8M from Viatris collaboration, with net loss of $15.5M and non-GAAP net loss of $2.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":64381000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191660,"accession_number":"0001104659-24-116774","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).","Net loss $12.7M vs $9.0M YoY; non-GAAP net loss from operations $2.9M vs $0.7M.","TRELEGY milestone: Q4 sales ~$260M needed for $25M payment, ~$610M for $50M; YTD sales $2.6B.","Board forms Strategic Review Committee to assess alternatives to unlock shareholder value.","CYPRESS (ampreloxetine) open-label enrollment on track for mid-2025 completion; data ~6 months later."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":45627000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208127,"accession_number":"0001104659-24-101816","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.","Qilu granted royalty-free license to market generic revfenacin on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation against three other ANDA filers (Cipla, Eugia, Mankind) remains pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208126,"accession_number":"0001104659-24-098326","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Theravance Biopharma presents at H.C. Wainwright conference; no material financial updates in slide deck","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management team to participate in fireside chat and one-on-one meetings at H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.","Slide presentation furnished as Exhibit 99.1 contains no new financial guidance or operational data beyond prior disclosures.","Filing is a procedural Regulation FD disclosure for investor presentation; no earnings, M&A, or leadership changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208125,"accession_number":"0001104659-24-085826","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.","Viatris collaboration revenue $14.3M, up 4% YoY; implied 35% share of YUPELRI net sales $19.1M (down 1%).","YUPELRI net sales (Viatris) $54.5M, down 1%; demand up 13% and hospital share hit all-time highs.","CYPRESS study: last patient enrollment now expected mid-2025; top-line data ~6 months later.","TRELEGY Q2 global net sales ~$1.1B (+40% YoY); up to $50M milestones achievable in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":28759000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225685,"accession_number":"0001104659-24-060536","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.","Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.","YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.","Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.","Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":14503000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225684,"accession_number":"0001104659-24-059338","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.","Ratified Ernst & Young as independent auditor for FY 2024 with 39,257,982 for, 228,078 against.","Non-binding advisory resolution on named executive officer compensation passed with 35,205,714 for, 332,345 against.","Total shares voted at annual meeting: 39,493,689 (81.3% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244843,"accession_number":"0001104659-24-028809","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.","The settlement resolves ongoing Hatch-Waxman litigation based on Lupin's ANDA for YUPELRI.","Patent litigation continues against three other ANDA filers: Cipla, Eugia Pharma, and Mankind Pharma.","Settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244842,"accession_number":"0001104659-24-027510","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma reports Q4 2023 GAAP net loss $8.5M; non-GAAP net profit $1.4M; YUPELRI net sales up 9% to $60.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 YUPELRI net sales recognized by Viatris grew 9% YoY to $60.6M record high; full-year Viatris collaboration revenue up 18% to $57.2M.","GAAP net loss of $8.5M in Q4; achieved non-GAAP net profit of $1.4M, driven by YUPELRI growth and expense management.","Completed $325M capital return program early Jan 2024, reducing shares outstanding by 37%.","YUPELRI hospital volumes grew 46% YoY, exceeding targets; CYPRESS study enrollment on track for H2 2024.","Ampreloxetine granted FDA Orphan Drug Designation; investor event planned for Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":57424000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244841,"accession_number":"0001104659-24-003852","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Patent settlement with Orbicular allows generic YUPELRI launch on April 23, 2039","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves Hatch-Waxman litigation with Orbicular over YUPELRI (revefenacin).","Orbicular granted royalty-free license to market generic revefenacin on or after April 23, 2039.","Litigation continues against four other ANDA filers: Cipla, Eugia, Lupin, and Mankind Pharma.","Settlement subject to review by U.S. DOJ and FTC as required by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244840,"accession_number":"0001104659-24-001556","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance Biopharma Phase 4 PIFR-2 study of YUPELRI fails to meet primary endpoint vs Spiriva HandiHaler in severe COPD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIFR-2 study did not show statistically significant difference on primary endpoint (change in trough FEV1 at Day 85) for YUPELRI vs Spiriva HandiHaler.","Both arms demonstrated similar lung function improvement; YUPELRI safety and tolerability consistent with prior studies.","Study enrolled adults with severe to very severe COPD (FEV1 <50% predicted) and suboptimal PIFR (<55 L/min).","CEO Rick E Winningham noted growth opportunities ahead for YUPELRI, an important COPD maintenance option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262290,"accession_number":"0001104659-23-129824","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Accord; generic entry allowed no earlier than April 23, 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement Agreement with Accord resolves Hatch-Waxman litigation over YUPELRI inhalation solution.","Accord granted royalty-free license to market generic YUPELRI on or after April 23, 2039, subject to customary exceptions.","Settlement subject to review by U.S. Department of Justice and Federal Trade Commission.","Patent litigation continues against five other ANDA filers: Cipla, Eugia, Lupin, Mankind, and Orbicular."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262289,"accession_number":"0001104659-23-128299","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Theravance Biopharma appoints Irenic's Jeremy Grant to board, enters cooperation agreement, reaffirms capital return","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeremy Grant appointed to Board as Class II director; Board temporarily expands to 10.","Cooperation agreement with Irenic includes standstill, voting commitments, and information sharing rights.","Company reaffirms commitment to return all excess capital; $300M returned since mid-2022, shares reduced ~35%.","Dr. Burton Malkiel not standing for re-election at May 2024 AGSM; Board will revert to 9 directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262288,"accession_number":"0001104659-23-115296","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Q3 loss narrows to $9.0M; YUPELRI sales up 9%; SVP R&D to depart Feb 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss from continuing ops $9.0M vs $16.0M prior year; non-GAAP loss $0.7M (improved from $7.1M).","YUPELRI net sales $58.3M (up 9% YoY, 6% QoQ); implied 35% share $20.4M.","Richard Graham, SVP R&D, to depart Feb 29, 2024; part-time from Jan 1; Áine Miller promoted to SVP Development.","Share buybacks $30.8M in Q3; $294.6M total; $30.4M remaining; program expected to complete by year-end 2023.","PIFR-2 study enrollment complete; top-line data Jan 2024. CYPRESS last patient enrollment H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":39859000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262287,"accession_number":"0001104659-23-112631","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Teva; generic launch delayed to April 2039","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Teva resolves ANDA litigation; Teva gets license to launch generic on or after April 23, 2039.","License is royalty-free, non-exclusive, non-sublicensable; subject to DOJ/FTC review and customary exceptions.","Litigation against six other ANDA filers (Accord, Cipla, Eugia, Lupin, Mankind, Orbicular) remains pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279481,"accession_number":"0001104659-23-099831","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Theravance Biopharma furnishes investor slide deck for H.C. Wainwright conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management team participating in fireside chat at H.C. Wainwright 25th Annual Global Investment Conference on Sep 12, 2023.","Slide presentation furnished as Exhibit 99.1 under Regulation FD; no specific financial or operational updates disclosed in the filing.","The filing does not contain earnings figures, guidance changes, or corporate developments beyond the conference schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279480,"accession_number":"0001104659-23-088346","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q2 2023: YUPELRI sales up 12% YoY; $80.5M in share buybacks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales recognized by Viatris: $55.0M, up 12% YoY; Theravance's 35% share implies $19.3M.","YUPELRI retail TRx and new-to-product TRx hit all-time highs, up 26% and 53% YoY (Symphony Health).","PIFR-2 enrollment nearing completion; top-line data late Q4 2023, disclosure expected Jan 2024.","$80.5M share repurchases in Q2 2023 ($263.8M cumulative); $61.2M remaining in $325M program to complete by year-end.","TRELEGY ELLIPTA Q2 global net sales $760M (+29% YoY); $50M milestone from Royalty Pharma if 2023 sales ≥ $2.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":24166000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297876,"accession_number":"0001104659-23-069993","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Pfizer terminates global license deal for Theravance's preclinical JAK inhibitor","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Termination effective Oct 7, 2023; Pfizer gave notice June 9, 2023.","Agreement covered preclinical skin-selective, locally acting pan-JAK inhibitor program.","No reason for termination or financial impact disclosed by Theravance.","Theravance regains rights to the program subject to wind-down obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297875,"accession_number":"0001104659-23-057152","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q1 2023 net loss narrows to $22.1M; YUPELRI sales up 8% to $47M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP net loss from continuing ops $22.1M vs $40.3M; non-GAAP net loss $14.9M vs $25.2M.","YUPELRI net sales (Viatris) $47M, +8% YoY; Theravance's 35% share $16.4M.","$215M of $325M buyback completed; $110M remaining; on track to finish by year-end.","CYPRESS Phase 3 study of ampreloxetine in MSA-nOH actively recruiting; enrollment expected H2 2024.","Jim Kelly (Weiss Asset Mgmt) appointed to Board; TRELEGY milestone $50M if 2023 global sales ≥ $2.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":10417000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297874,"accession_number":"0001104659-23-055518","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Theravance shareholders approve 46% reduction in equity plan shares and board declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2013 Equity Incentive Plan: extended term 10 years, eliminated evergreen, reduced shares reserved by 3,808,287 (46% reduction).","Shareholders approved amendment to declassify Board of Directors over time.","Director nominees elected: Dean J. Mitchell and Deepika R. Pakianathan elected Class III directors.","Ernst & Young ratified as independent auditor for fiscal year ending Dec 31, 2023.","Non-binding advisory vote on executive compensation approved; shareholders voted for annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297873,"accession_number":"0001104659-23-045844","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Theravance Biopharma presents at Needham Healthcare Conference; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management team presented at 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023.","Slide deck furnished as Exhibit 99.1 contains only a title slide; no financial or pipeline updates provided.","Filing under Item 7.01 is for Regulation FD purposes and is not deemed filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297872,"accession_number":"0001104659-23-044043","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Theravance Biopharma appoints James C. Kelly as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James C. Kelly appointed to Board on April 11, 2023, as Class I director through 2024 AGM.","Kelly is Managing Director at Weiss Asset Management, joined in 2010.","He waived equity component of director compensation; standard indemnification agreement in place.","Board size increased to 10, will revert to 9 after Annual Meeting; Kelly deemed independent.","As of March 6, 2023, Kelly beneficially owned 0 ordinary shares of Theravance Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318126,"accession_number":"0001104659-23-031420","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Theravance Biopharma confirms zero exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company states it holds no cash deposits or securities at Silicon Valley Bank.","Disclosure addresses potential investor concerns about SVB's March 2023 collapse.","No financial impact or operational disruption related to SVB's failure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318122,"accession_number":"0001104659-23-027339","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K/A","filed_at":"2023-03-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Theravance Biopharma discloses separation terms for departing CFO Andrew Hindman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation agreement includes lump sum of 24 weeks base salary and 100% of 2022 target cash bonus.","Company to pay up to 9 months COBRA premiums.","20,000 performance-based RSUs vested (performance criteria met).","Hindman eligible for change in control severance if change in control within 3 months after Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318125,"accession_number":"0001104659-23-026404","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance Biopharma increases buyback to $325M, announces formal strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Capital Return Program increased to $325M; $170M remaining expected by end of 2023; $27M repurchased YTD 2023.","Q4 2022 YUPELRI sales $19.5M (up 27% YoY); TRELEGY global net sales $537M (up 13% YoY).","Non-GAAP profit expected in 2H 2023; 2023 R&D guidance $35-45M, SG&A $45-55M.","Appointed Susannah Gray (ex-Royalty Pharma CFO) to Board; Board declassification proposal submitted.","Announced formal strategic review; responding to Irenic Capital's activist claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318124,"accession_number":"0001104659-23-026064","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Theravance Biopharma upsizes buyback to $325M, cuts 17% staff, appoints new director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Capital return program increased to $325M; $170M remaining; $155M repurchased to date.","Discontinuing research investments, reducing headcount by ~17%; inhaled JAK program to be partnered.","Q4 2022 YUPELRI net sales $19.5M (TBPH implied 35% share), up 27% YoY; total revenue $14.6M.","Appointed Susannah Gray to Board; William D. Young not standing for re-election; Board declassification proposal at May 2 AGM.","2023 guidance: R&D $35-45M, SG&A $45-55M; non-GAAP profit expected in 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318123,"accession_number":"0001104659-23-001980","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma highlights YUPELRI growth, $250M buyback progress, and ampreloxetine Phase 3 start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["YUPELRI achieved all-time high net sales and profit in Q2 and Q3 2022; expects continued Q4 growth.","$250M capital return program ~50% completed as of 12/31/2022; ~$95M GSK buyback and ~$33M open market repurchases.","Ampreloxetine Phase 3 CYPRESS trial in MSA patients with nOH to start Q1 2023; orphan drug submission planned.","Targeting Non-GAAP profitability by 2H 2023; $50M milestone if TRELEGY sales reach ~$2.86B in 2023.","Sale of TRELEGY royalty interests for $1.1B upfront eliminated all debt; financial restructuring completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336407,"accession_number":"0001104659-22-126067","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Theravance Biopharma CFO Andrew Hindman to depart Dec 31; Aziz Sawaf named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Hindman, SVP and CFO, will leave on December 31, 2022.","Aziz Sawaf appointed CFO effective Jan 1, 2023; previously VP of Finance since Oct 2021.","Sawaf joined Theravance in 2014; prior roles at Gilead Sciences, Amgen, and consulting.","Sawaf holds CFA charter, MBA from USC, and MBEE from Johns Hopkins University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336404,"accession_number":"0001104659-22-117504","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K/A","filed_at":"2022-11-14T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Theravance Biopharma completes sale of TRC units to Royalty Pharma for $1.107 billion cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 2,125 Class B and 6,375 Class C units of Theravance Respiratory Company to Royalty Pharma on July 20, 2022.","Total cash consideration of $1.107 billion, net of $420 million payoff of 9.5% non-recourse notes due 2035.","Pro forma net gain of approximately $931.8 million recorded, with estimated income tax payable of $120.6 million.","Pro forma financials show elimination of $148.3 million equity investment and $396.1 million non-recourse notes.","Transaction qualifies as discontinued operations; pro forma net loss of $68.1 million for six months ended June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336406,"accession_number":"0001104659-22-115424","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q3 2022: YUPELRI sales up 35% YoY; $1.1B TRELEGY deal closed; debt-free","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Implied 35% share of YUPELRI net sales $18.7M, up 35% YoY; Viatris collaboration revenue $12.4M.","Closed TRELEGY royalty sale to Royalty Pharma for ~$1.1B upfront; gain of $1.14B; now debt-free with $486.8M cash.","Initiated $250M capital return; purchased GSK's 9.6M shares at $9.75/shr; Dutch tender up to $95M extended to Nov 17.","Operating expenses guidance: R&D $45-55M, SG&A $35-45M for FY2022 (excl. share-based comp and one-time costs).","Ampreloxetine Phase 3 study (CYPRESS) in MSA patients with nOH to start Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":11.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":36697000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-07T23:59:59+00:00|336406"}